Priorix (measles, mumps, and rubella vaccine, live) – New vaccine approval

- On June 6, 2022, GSK announced the FDA approval of Priorix (measles, mumps, and rubella vaccine, live), for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

- Measles, mumps and rubella are acute and highly-contagious viral diseases.

    - According to a recent Centers for Disease Control and Prevention (CDC) report, vaccine ordering in the past two years through the CDC's Vaccines for Children program, the federal program through which about half of the children in the country are immunized, dropped more than 10%, indicating that fewer vaccinations in children were occurring.

- The efficacy of Priorix was demonstrated based on immunogenicity data vs. a comparator vaccine.

- Priorix is scheduled to be on the agenda for the June CDC Advisory Committee on Immunization Practices (ACIP) meeting for consideration of formal inclusion into the vaccine schedule and recommendations.

- Priorix is contraindicated in patients:

    - With a history of severe allergic reactions (eg, anaphylaxis) to any component of the vaccine or after a previous dose of any measles, mumps, and rubella virus-containing vaccine
    - With severe humoral or cellular (primary or acquired) immunodeficiency
    - Who are pregnant.

- Warnings and precautions for Priorix include allergic vaccine reactions, febrile seizures, thrombocytopenia, syncope, latex, risk of vaccine virus transmission, and limitation of vaccine effectiveness.

- The most common adverse reactions with Priorix use in patients 12 through 15 months of age: local reactions (pain and redness); systemic reactions (irritability, loss of appetite, drowsiness, and fever). In patients 4 through 6 years of age: local reactions (pain, redness, and swelling); systemic reactions (loss of appetite, drowsiness, and fever). In patients 7 years of age and older: local reactions (pain and redness).

- Priorix is administered according to the following schedule:

    - First dose – 12 through 15 months of age
    - Second dose – 4 through 6 years of age

- If Priorix is not administered according to this schedule and 2 doses of measles-, mumps- and rubella-virus vaccine are recommended for an individual, there should be a minimum of 4 weeks between the first and second dose.

- Priorix may be administered as a second dose to individuals who have received a first dose of another measles, mumps, and rubella virus-containing vaccine.

Continued . . .

- GSK's launch plans for Priorix are pending. Priorix will be available as a single-dose vial of lyophilized antigen component to be reconstituted with the accompanying prefilled syringe of sterile water diluent. A single dose after reconstitution is approximately 0.5 mL